文献速递类风湿关节炎

SB4与依那西普转换治疗的长期疗效与安全性

Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4.
PubMed 文献 · Ann Rheum Dis · 2017-11-13

在随机双盲52周研究中,SB4与依那西普(ETN)疗效安全性相当;开放扩展期评估继续SB4或从ETN转换至SB4的长期疗效安全性及免疫原性。245例患者入组扩展期,SB4/SB4组126例,ETN/SB4组119例。第100周ACR20应答率分别为77.9%和79.1%,其他疗效指标及影像学进展两组相当。转换未增加安全风险。

要点

  • SB4治疗类风湿关节炎(RA)2年有效且耐受良好。
  • 从ETN转换至SB4后疗效、安全性与继续SB4相当。
  • 转换未增加抗药抗体产生风险。

核心结论

  • SB4在RA患者中2年内有效且耐受良好,继续SB4与从ETN转换至SB4的疗效、安全性和免疫原性相当,转换无风险。

研究设计与样本

  • 随机双盲52周研究后开放扩展期,完成52周访视的捷克和波兰患者接受SB4治疗48周,评估至第100周。

主要发现

  • 第100周ACR20应答率SB4/SB4组77.9%,ETN/SB4组79.1%,其他疗效包括影像学进展两组相当。
  • 第52周后治疗中出现的不良事件率SB4/SB4组47.6%,ETN/SB4组48.7%;每组1例产生非中和性抗药抗体。
  • 扩展期未报告活动性结核或注射部位反应;SB4/SB4组1例死于肝癌。

关键数值与推荐

  • 随机双盲期每周皮下注射SB4或ETN 50mg联合背景甲氨蝶呤至52周。
  • 扩展期继续SB4或转换为SB4,再治疗48周,评估至第100周。

临床怎么用

  • RA患者长期使用SB4有效安全,从ETN转换至SB4不增加风险。

局限性

  • 扩展期仅纳入捷克和波兰完成52周访视的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: SB4 (Benepali, Brenzys) is a biosimilar of reference etanercept (ETN). In a randomised, double-blind, 52-week study, SB4 demonstrated comparable efficacy and safety to ETN in patients with rheumatoid arthritis (RA). The open-label extension period evaluated long-term efficacy, safety and immunogenicity when continuing SB4 versus switching from ETN to SB4. METHODS: In the randomised, double-blind phase, patients received weekly subcutaneous administration of 50 mg SB4 or ETN with background methotrexate for up to 52 weeks. Patients in the Czech Republic and Poland who completed the 52-week visit were enrolled in the open-label extension period and received SB4 for 48 additional weeks. Efficacy, safety and immunogenicity were assessed up to week 100. RESULTS: Of 245 patients entering the extension period, 126 continued to receive SB4 (SB4/SB4) and 119 switched to SB4 (ETN/SB4). American College of Rheumatology (ACR) response rates were sustained and comparable between SB4/SB4 and ETN/SB4 with ACR20 response rates at week 100 of 77.9% and 79.1%, respectively. Other efficacy results, including radiographic progression, were also comparable between the groups. After week 52, rates of treatment-emergent adverse events were 47.6% (SB4/SB4) and 48.7% (ETN/SB4); one patient/group developed non-neutralising antidrug antibodies. No cases of active tuberculosis or injection-site reactions were reported during the extension period. One patient (SB4/SB4) died of hepatic cancer. CONCLUSIONS: SB4 was effective and well tolerated over 2 years in patients with RA. Efficacy, safety and immunogenicity were comparable between the SB4/SB4 and ETN/SB4 groups, showing no risk associated with switching patients from ETN to SB4. TRIAL REGISTRATION NUMBER: NCT01895309; 2012-005026-30.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Emery P, Vencovský J, Sylwestrzak A, et al. Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4. Ann Rheum Dis. 2017. PMID: 28794078. doi:10.1136/annrheumdis-2017-211591

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。